ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,00%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
80,815
0,01%
Bitcoin
68 658,36
1,35%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MaxCyte Inc (MXCT)

  7. MaxCyte Inc (MXCT) Actualités

MXCT

MaxCyte (MXCT)

MaxCyte Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MXCT
DateHeureSourceTitreSymboleSociété
29/05/202414h05GlobeNewswire Inc.MaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceNASDAQ:MXCTMaxCyte Inc
22/05/202414h05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentNASDAQ:MXCTMaxCyte Inc
07/05/202423h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MXCTMaxCyte Inc
07/05/202422h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MXCTMaxCyte Inc
07/05/202422h05GlobeNewswire Inc.MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
10/04/202414h05GlobeNewswire Inc.MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024NASDAQ:MXCTMaxCyte Inc
02/04/202414h05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)NASDAQ:MXCTMaxCyte Inc
12/03/202421h05GlobeNewswire Inc.MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
04/03/202423h39Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MXCTMaxCyte Inc
04/03/202422h05GlobeNewswire Inc.MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsNASDAQ:MXCTMaxCyte Inc
26/02/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MXCTMaxCyte Inc
14/02/202422h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MXCTMaxCyte Inc
14/02/202418h25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MXCTMaxCyte Inc
09/02/202414h05GlobeNewswire Inc.MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesNASDAQ:MXCTMaxCyte Inc
30/01/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MXCTMaxCyte Inc
30/01/202414h05GlobeNewswire Inc.MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersNASDAQ:MXCTMaxCyte Inc
23/01/202414h05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy ProgramsNASDAQ:MXCTMaxCyte Inc
08/01/202422h05GlobeNewswire Inc.MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MXCTMaxCyte Inc
03/01/202414h05GlobeNewswire Inc.MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell PipelineNASDAQ:MXCTMaxCyte Inc
02/01/202408h00GlobeNewswire Inc.MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and DirectorNASDAQ:MXCTMaxCyte Inc
11/12/202322h05GlobeNewswire Inc.MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023NASDAQ:MXCTMaxCyte Inc
16/11/202314h05GlobeNewswire Inc.MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding MemberNASDAQ:MXCTMaxCyte Inc
08/11/202322h05GlobeNewswire Inc.MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue GuidanceNASDAQ:MXCTMaxCyte Inc
06/11/202322h05GlobeNewswire Inc.MaxCyte to Participate in Two Upcoming Investor ConferencesNASDAQ:MXCTMaxCyte Inc
04/10/202322h05GlobeNewswire Inc.MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue GuidanceNASDAQ:MXCTMaxCyte Inc
06/09/202314h05GlobeNewswire Inc.MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingNASDAQ:MXCTMaxCyte Inc
05/09/202314h05GlobeNewswire Inc.MaxCyte to Participate in Baird Global Healthcare ConferenceNASDAQ:MXCTMaxCyte Inc
09/08/202322h05GlobeNewswire Inc.MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 GuidanceNASDAQ:MXCTMaxCyte Inc
01/08/202314h05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for PatientsNASDAQ:MXCTMaxCyte Inc
13/07/202314h05GlobeNewswire Inc.MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023NASDAQ:MXCTMaxCyte Inc
 Showing the most relevant articles for your search:NASDAQ:MXCT

Dernières Valeurs Consultées

EU
BN
Danone
EU
BEL20
Bel 20
EU
EN
Bouygues
EU
GLE
Societe Generale
NYSE
KO
Coca Cola
EU
LR
Legrand
EU
DG
Vinci
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
EU
MC
Lvmh Moet Hennessy Louis...
EU
PX4
SBF 120
EU
ORA
Orange
NASDAQ
AMZN
Amazon.com
EU
AI
Air Liquide
EU
SGO
Cie de SaintGobain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés